News S3-E37.4 – The “Pincer Movement” In Cirrhosis Technology: Patient Support vs High-End MedTech Jul 24, 2022 S3-E73.3 – Where Is The Next Cirrhosis Breakthrough? Jul 24, 2022 S3-E37.2 – Can Today’s Medicines Cause Fibrosis Regression in Cirrhosis Patients? Jul 24, 2022 S3-E37.1 – Cirrhosis Screening & Diagnostic Tests Jul 24, 2022 S3-E37 – What Do We Know That Can Help NASH Cirrhosis Patients Today? Posted 1 year ago1 year ago Jul 21, 2022 S3-E36.5 – REGENERATE Redux: Clearing The Finish Line? Jul 17, 2022 S3-E36.4 – REGENERATE Redux: Other Obeticholic Acid (OCA) Questions Jul 17, 2022 S3-E36.3 – REGENERATE Redux: Safety and Tolerability With Obeticholic Acid Jul 17, 2022 S3-E36.2 – REGENERATE Redux: What OCA Efficacy Results Mean For Patients Jul 16, 2022 S3-E36.1 – REGENERATE Redux: Obeticholic Acid (OCA) Efficacy Jul 16, 2022 S3-E36 – REGENERATE Redux – Can OCA Succeed With New Data? Jul 14, 2022 S3-E35.5 – Liver Science At #ILC2022: Mid-Range Impact of Advances Jul 11, 2022 « Older Entries Next Entries »
S3-E37.4 – The “Pincer Movement” In Cirrhosis Technology: Patient Support vs High-End MedTech Jul 24, 2022
S3-E37 – What Do We Know That Can Help NASH Cirrhosis Patients Today? Posted 1 year ago1 year ago Jul 21, 2022